Unbiased Analysis of Today's Healthcare Issues
That is the title of a new paper with Shanshan Wang, Jaehong Kim, and Slaven Sikirica that has the subtitle “Budget impact analysis from the US payer perspective.” That abstract is below: BACKGROUND:Heart failure (HF) is a leading cause of mortality in the United States, often complicated by comorbidities like diabetes mellitus. These patients face…
Perhaps not. At least that is according to a paper by Anderson et al. (2024). The authors use a difference-in-difference approach with 2018-2021 claims data. A summary of the results are below. Approximately one-quarter of patients who use insulin report underuse because of cost. In response, more than twenty states have implemented monthly caps on…
That is the title of my article with Jaehong Kim, Shanshan Wang and Slaven Sikirica in the Journal of Comparative Effectiveness Research. The abstract is below. Aim: To assesses the cost–effectiveness of sotagliflozin for the treatment of patients hospitalized with heart failure and comorbid diabetes. Materials & methods: A de novo cost–effectiveness model with a Markov structure was created…
Can voice-based AI help patients with diabetes move more quickly towards optimal insulin dosing? According to a Nayak et al. (2023) study out today in JAMA Network Open, the answer is yes. Question Can a voice-based conversational artificial intelligence (AI) application help patients with type 2 diabetes titrate basal insulin at home to achieve rapid…
What is the impact of being insured on health outcomes? This is a difficult question to answer in part because of adverse selection (e.g., sicker patients may choose to be insured). But even absent adverse selection, the ability to diagnosis a disease may vary between the insurer and uninsured. Consider this example from Kaliski (2023):…
Conventional wisdom would hold that the prices are rising…aren’t they? To correctly answer this question, one must define which prices you are talking about. Are we looking at the list price that is widely available or the net price after we take into account discounts are rebates life sciences firms pay? A paper by Sarpatwari…
Please check out my latest publication in Value in Health titled “Value-Based Payments and Incentives to Improve Care: A Case Study of Patients with Type 2 Diabetes in Medicare Advantage“. This work is based on research conducted with my co-authors Jesse Sussell, Kata Bognar, Taylor T. Schwartz, John J. Sheehan, Wade Aubry, and Dennis Scanlon,…
In April 2006, Ontario instituted the Diabetes Management Incentive (DMI) that increased payments to physicians that provided high-quality diabetes care. Did the incentive improve payments quality? According to a paper by Kantarevic and Kralj (2012), it turns out that the answer is yes, but the magnitude of the change depends on the type of physician.…